A recent lightning rod for abortion opponents, the drug mifepristone—the first of two in the standard medication abortion regimen—surfaced several times during Robert F. Kennedy, Jr.’s first Senate confirmation hearing as President Trump’s pick for Health and Human Services secretary.

Robert F. Kennedy Jr had an absolute trainwreck of a confirmation hearing. Kennedy, who had been a vocal vaccine skeptic and preached numerous disproven conspiracy theories, was lambasted for his anti-science stance and his refusal to stop suing the very companies he now wants to regulate.

A higher dose of an emergency-contraception drug may open a back door for Americans seeking abortions in restrictive states.

Meanwhile, in an executive order, Trump created his long-discussed “Department of Government Efficiency,” to be led by Elon Musk, the world’s richest man. On paper, the department is tasked with modernizing federal technology and software; however, Trump and Musk have spent months boasting about how it will gut the federal government.

Last Friday, my colleague Julianne McShane and I broke the news of a pair of letters sent by 30 prominent anti-abortion movement leaders to the heads of the Departments of Health and Human Services and Justice, asking them to use the powers of their agencies to attack abortion pills.

Robert F. Kennedy Jr. made several disturbing comments during his first Senate confirmation hearing Wednesday suggesting that, as Donald Trump’s secretary of health and human services, he’s hoping to limit access to the abortion pill mifepristone.

The three states argue that the FDA's approval of mifepristone for use up to 10 weeks of pregnancy, along with its availability via telemedicine and mail, has contributed to what they view as a public health risk.

A new study shows a possible new abortion drug to replace mifepristone. But will these results increase abortion access—or restrict women's reproductive health options down the line?

A decision by a federal judge last week is reviving the effort to limit access to mifepristone, opening a fresh round of litigation over a widely used drug that has grown in importance since the ...

In 2022, a coalition of groups that oppose abortion sued the FDA in an effort to pull mifepristone off the market. In June, the Supreme Court unanimously struck down the challenge, ruling that the ...

Robert F. Kennedy, Jr, faced another day of tough questioning today in the second of his two confirmation hearings for his nomination to be Secretary of the Department of Health and Human Services (HHS), declining to distance himself from previous statements he has made linking childhood vaccines to autism.

The anti-abortion movement has launched a pressure campaign urging President Donald Trump’s administration to take steps toward a nationwide ban on medication abortion, the method used in nearly two-thirds of all abortions nationwide.